1174013-24-1

Basic information

• Product Name: (R)-Methyl 3-cyclopentyl-2-hydroxypropanoate
• Synonyms: (R)-Methyl 3-cyclopentyl-2-hydroxypropanoate;Methyl3-cyclopentyl-2-(R)-hydroxypropanoate;methyl(R)-3-cyclopentyl-2-hydroxypropanoate;EOS-60685
• CAS NO: 1174013-24-1
• Molecular Formula: C₉H₁₆O₃
• Molecular Weight: 172.22154
• Mol File: 1174013-24-1.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (R)-Methyl 3-cyclopentyl-2-hydroxypropanoate(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-Methyl 3-cyclopentyl-2-hydroxypropanoate(1174013-24-1)
• EPA Substance Registry System: (R)-Methyl 3-cyclopentyl-2-hydroxypropanoate(1174013-24-1)

Safety Data

• Hazardous Substances Data: 1174013-24-1(Hazardous Substances Data)

Usage

Description

(R)-methyl 3-cyclopentyl-2-hydroxypropanoate, with the molecular formula C10H18O3, is a chemical compound that represents the (R)-enantiomer of methyl 3-cyclopentyl-2-hydroxypropanoate. It is characterized by its unique structure and properties, which make it a valuable asset in the field of chemical synthesis and pharmaceutical development.

Uses

Used in Pharmaceutical Synthesis:
(R)-methyl 3-cyclopentyl-2-hydroxypropanoate is used as a chiral intermediate for the synthesis of various pharmaceuticals. Its specific stereochemistry is crucial in the development of medicines with targeted effects and reduced side effects.
Used in Agrochemical Production:
In the agrochemical industry, (R)-methyl 3-cyclopentyl-2-hydroxypropanoate is utilized as a key component in the production of different agrochemicals, contributing to the development of more effective and environmentally friendly products.
Used in Organic Synthesis:
As a building block in organic synthesis, (R)-methyl 3-cyclopentyl-2-hydroxypropanoate is employed to create complex molecules with specific stereochemistry, which are essential in various chemical and pharmaceutical applications.
Used in Research and Development:
(R)-methyl 3-cyclopentyl-2-hydroxypropanoate is also used in research and development to create new chemicals and drugs with potential therapeutic applications, further expanding its utility in the scientific community.

Upstream product

• 916606-87-6 3-cyclopentylpropane-1,2-diol 
• 186581-53-3 diazomethane 
• 35468-70-3 2-Hydroxy-3-cyclopentyl-propionsaeure 
• 1401513-92-5 C₉H₁₄O₃ 
• 4538-50-5 methyl (2R)-glycidate 
• 33240-34-5 cyclopentylmagnesium bromide 
• 67-56-1 methanol 

Downstream Products

• 1174013-25-2 (R)-methyl 3-cyclopentyl-2-(((trifluoromethyl)sulfonyl)oxy)-propanoate 
• 1215197-37-7 (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid 
• 1215197-36-6 (S)-benzyl 6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinate 
• 1215198-58-5 (S)-benzyl 6-(2-(4-(cyclobutylsulfonyl)-1H-imidazol-1-yl)-3-cyclopentylpropanamido)nicotinate 

Relevant articles and documents

A chemoselective oxidation of monosubstituted ethylene glycol: Facile synthesis of optically active α-hydroxy acids

A mild and efficient method for the synthesis of optically active α-hydroxy acids through chemoselective oxidation of monosubstituted ethylene glycols using the TEMPO-NaOCl reagent system is described. It is evident from our studies that the solvent, pH and reaction temperature are very crucial for the success of this oxidation. The versatility of this method has been demonstrated with a variety of aliphatic, aromatic and carbohydrate substrates bearing various functional groups. the Partner Organisations 2014.

Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl) propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus

Glucokinase is a key regulator of glucose homeostasis, and small molecule allosteric activators of this enzyme represent a promising opportunity for the treatment of type 2 diabetes. Systemically acting glucokinase activators (liver and pancreas) have bee

HETEROARYLS AMIDE DERIVATIVES AND THEIR USE AS GLUCOKINASE ACTIVATORS

The present invention provides Formula (1A) compounds that act as glucokinase activators; pharmaceutical compositions thereof; and methods of treating diseases, disorders, or conditions mediated by glucokinase. X, Y, Z, R1, R2, R3, and R4 are as described herein.